Filing identity and period
Important identity mismatch: The request identifies T3 Defense Inc., but the supplied filing is Nukkleus Inc. (Nasdaq: NUKK; warrants: NUKKW), Form 10-Q, for the quarter ended March 31, 2024, filed August 14, 2024. The summary below reflects the supplied Nukkleus filing, not a T3 Defense filing.
Nukkleus is a financial technology company providing foreign-exchange trading technology and financial/payment services. Its December 22, 2023 business combination was accounted for as a reverse recapitalization. The financial statements cover the three- and six-month periods ended March 31, 2024, compared with the corresponding 2023 periods.
Financial results and position
| Metric | Three months ended March 31, 2024 | Six months ended March 31, 2024 |
|---|---|---|
| Revenue | $259,757 | $5,502,148 |
| Gross profit | $196,561 | $655,261 |
| Operating expenses | $2,616,410 | $12,022,339 |
| Net loss | $2,429,417 | $11,357,512 |
| Basic and diluted loss per share | $0.17 | $0.92 |
- Quarterly financial-services revenue was $259,757, with a 75.7% segment gross margin. Six-month financial-services revenue was $702,148, with a 72.0% segment gross margin. General-support-services revenue was $4.8 million in the six-month period, all recognized before the agreement’s termination effective January 1, 2024.
- Professional fees were $4.90 million for six months; bad-debt expense was $6.15 million, recorded in December 2023 in connection with TCM-related receivables. The filing also reports $2.77 million of shares issued for services during the six months.
- At March 31, total assets were $1.23 million, total liabilities $12.75 million, and stockholders’ deficit $11.52 million. Current assets of $808,253 compared with current liabilities of $11.79 million, yielding a $10.98 million working-capital deficit.
- Cash was $305,589, excluding $345,631 of customer custodial cash. Six-month operating cash flow was negative $1.88 million; investing cash flow was positive $131,492 and financing cash flow positive $1.67 million. Ending cash including customer custodial cash was $651,220.
- Related-party loans payable totaled approximately $1.67 million ($732,324 current and $941,000 non-current). A further $7.98 million was due to affiliates; these balances are described as short-term, unsecured, non-interest-bearing, and repayable on demand. Total liabilities were $12.75 million.
Material changes versus prior comparable periods
- Quarterly revenue fell 95.4%, from $5.63 million to $259,757, as related-party general-support revenue ceased and financial-services revenue declined 68.9%. Six-month revenue was down 50.0%, to $5.50 million.
- Quarterly net loss increased to $2.43 million from $806,000. Six-month net loss increased to $11.36 million from $1.94 million, driven largely by the $6.15 million bad-debt provision and higher professional fees.
- Financial-services gross profit improved from $72,962 to $196,561 for the quarter, and from a $56,911 loss to $505,261 for six months. Management attributes much of the margin comparison to lower costs after impairment of Match-acquired intangible assets in September 2023.
- Financial-services trading volume decreased to $33.1 million for the quarter from $288.8 million, and to $102.5 million for six months from $430.7 million. Active clients for the six-month period declined to 66 from 127.
- Working-capital deficit widened by $4.79 million from September 30, 2023. Cash excluding customer funds increased from $19,318 to $305,589, but remains very limited relative to obligations.
Outlook, risks, contingencies, and unusual items
- Going concern: Management states that available cash is not expected to cover operating expenses for the next 12 months and that substantial doubt exists about the company’s ability to continue as a going concern. It expects to seek additional equity or debt financing, with no assurance of availability or acceptable terms; no committed future funding was reported in the liquidity discussion.
- Customer and related-party exposure: TCM did not pay under the GSA, which provided for at least $1.6 million monthly. The company advised that the agreement was terminated effective January 1, 2024, wrote off related-party receivables, and does not expect general-support revenue until it obtains other customers. Related parties also account for substantial balances due to and from affiliates and related-party financing.
- Management outlook: Management expected financial-services revenue and gross margin to remain near current quarterly levels, with minimal near-term increase. It expected professional fees to decrease, while compensation and certain other expenses were expected to remain near current levels.
- Subsequent financing and dilution: In June 2024, the company issued a $312,500 principal note for $250,000 cash, at 12% interest, with a $0.25 conversion price and warrants for 1.2 million shares; the lender had a potential additional $500,000 financing right and financing restrictions applied during the investment period. In August 2024, it issued a $515,500 principal note for $412,075 cash, also at 12%, convertible at $0.25, with warrants for 1.4 million shares.
- Other subsequent events: A May 2024 settlement with Silverback Capital concerned $1.12 million of vendor payables to be settled in shares; the filing reports 1,889,550 shares issued through July 22. In July, 500,000 shares were issued for accrued professional fees and 300,000 for services. Emil Assentato resigned as CEO and director on July 24, 2024; Jamal Khurshid became CEO.
- Disclosure controls and procedures were assessed as ineffective at March 31, 2024 due to previously reported, unremediated material weaknesses. Management stated that additional procedures supported fair presentation of the interim statements. The filing reports no material legal proceedings and no off-balance-sheet arrangements.
Key facts for investors to verify
- Confirm the issuer and reporting period: the supplied document is Nukkleus Inc.’s March 31, 2024 Form 10-Q, not a T3 Defense filing.
- Review collectability and status of TCM receivables, the GSA termination, the $6.15 million bad-debt provision, and the remaining related-party balances.
- Assess near-term liquidity, affiliate advances and loans, and the terms, restrictions, conversion rights, and dilution from post-quarter financings.
- Reconcile post-quarter share issuances and warrants with the reported 16,791,964 shares outstanding as of August 12, 2024.
- Track remediation of material weaknesses and any change in the company’s going-concern assessment.